Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 11, 2018 08:00 ET | Source: Atossa Genetics Inc.

Atossa Genetics Completes Enrollment in Phase 2 Study of Topical Endoxifen in Women with Mammographic Breast Density

SEATTLE, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and...
September 13, 2018 08:00 ET | Source: Atossa Genetics Inc.

Atossa Genetics Announces Preliminary Results from Male Phase 1 Study of Topical Endoxifen

***All Objectives Successfully Met*** Conference Call to Be Held Today at 10 am Eastern Time SEATTLE, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a...
September 12, 2018 08:00 ET | Source: Atossa Genetics Inc.

Atossa Genetics to Host Conference Call to Announce Preliminary Results from Male Phase 1 Study of Topical Endoxifen Thursday, September 13, 2018 at 10 am EDT

SEATTLE, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and...
August 13, 2018 16:15 ET | Source: Atossa Genetics Inc.

Atossa Genetics Announces Second Quarter 2018 Financial Results And Provides Company Update

SEATTLE, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer...
August 01, 2018 08:00 ET | Source: Atossa Genetics Inc.

Atossa Genetics Contracts with Additional Manufacturer of Endoxifen

SEATTLE, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to...
July 18, 2018 08:00 ET | Source: Atossa Genetics Inc.

Atossa Genetics Announces Intraductal Microcatheter ImmunoOncology Pre-Clinical Program

SEATTLE, July 18, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to...
July 13, 2018 08:00 ET | Source: Atossa Genetics Inc.

Atossa Genetics Opens Enrollment in Phase 2 Study of Oral Endoxifen to Treat Breast Cancer

SEATTLE, July 13, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to...
June 26, 2018 08:00 ET | Source: Atossa Genetics Inc.

Atossa Genetics Opens Its Phase 2 Study of Topical Endoxifen to Treat Mammographic Breast Density

SEATTLE, June 26, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to...
June 20, 2018 08:00 ET | Source: Atossa Genetics Inc.

Atossa Genetics Completes all Dosing and Clinical Visits in its Phase 1 Study of Topical Endoxifen in Men

SEATTLE, June 20, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to...
June 14, 2018 08:00 ET | Source: Atossa Genetics Inc.

Atossa Genetics Appoints Two Additional Prominent Industry Executives to Strategic Advisory Board

SEATTLE, June 14, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods...